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ABSTRACT 
Mass spectrometry analysis of renal cancer cell lines recently suggested that the Protein-
Tyrosine Phosphatase Receptor Type J (PTPRJ), an important regulator of tyrosine kinase 
receptors, is tightly linked to the von-Hippel Lindau protein (pVHL). Therefore, we aimed to 
characterize the biological relevance of PTPRJ for clear cell renal cell carcinoma (ccRCC). In 
pVHL negative ccRCC cell lines both RNA and protein expression levels of PTPRJ were 
lower than those in the corresponding pVHL reconstituted cells. Quantitative RT-PCR and 
Western blot analysis of ccRCC with known VHL mutation status and normal matched tissues 
as well as RNA in situ hybridization on a Tissue Microarray (TMA) confirmed a decrease of 
PTPRJ expression in more than 80 % of ccRCCs, but in only 12 % of papillary RCCs. ccRCC 
patients with no or reduced PTPRJ mRNA expression had a less favourable outcome than 
those with a normal expression status (p=0.05). Sequence analysis of 32 PTPRJ mRNA 
negative ccRCC samples showed five known polymorphisms, but no mutations implying 
other mechanisms leading to PTPRJ’s down-regulation. Selective silencing of HIF-Į by 
siRNA and reporter gene assays demonstrated that pVHL inactivation reduces PTPRJ 
expression through a HIF-dependent mechanism, which is mainly driven by HIF-2Į 
stabilization. Our results suggest PTPRJ as a member of a pVHL controlled pathway whose 
suppression by HIF is critical for ccRCC development.  
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INTRODUCTION 
Most clear cell renal cell carcinomas (ccRCC) are characterized by a bi-allelic somatic 
inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene [1]. The VHL protein 
(pVHL) is an important regulator of the Hypoxia Inducible Factor-Į (HIF-Į), microtubule 
stabilization, maintenance of the primary cilium, mitotic regulation and cell mobility [2]. The 
loss of function of pVHL leads to HIF-Į stabilization and up-regulation of HIF target genes 
which are involved in cell growth and proliferation, angiogenesis, invasion and metastasis. 
Examples of up-regulated HIF-target genes are VEGF-A, EPO, EGFR and CAIX [3] which 
represent also potential anticancer drug targets. Data about genes and proteins down-regulated 
due to pVHL functional deficiency are rare. Examples include important genes/proteins such 
as fibronectin [4], E-cadherin [5], PAX2 [6] and p53 [7]. 
 
Recent mass spectrometry experiments with ccRCC cell lines [8] showed that the 
expression of the protein tyrosine phosphatase receptor type J (PTPRJ) is associated with the 
presence of pVHL. PTPRJ is composed of an extracellular domain that contains eight 
fibronectin type III repeats, a transmembrane domain, and a cytoplasmic end comprising a 
single catalytic domain [9]. In vitro, the receptor is involved in the regulation of cellular 
differentiation, proliferation, growth and migration [10-14] which supports its potential 
relevance for cancer development. In colon, lung and breast cancer PTPRJ is affected by 
allelic imbalances and missense mutations [15, 16]. Furthermore, several membrane-
associated tyrosine kinase receptors are controlled by PTPRJ, among them there are 
established or potential molecular anti-cancer drug targets, e.g. EGFR [17], PDGFR-ȕ [18], 
VEGFR2 [19] and HGFR (also termed c-MET) [20]. 
 
To date the molecular mechanisms leading to down-regulation of PTPRJ expression in 
ccRCC are unknown. Consequently, here we investigated the influence of the pVHL-HIF axis 
on PTPRJ expression in human ccRCC. 
 
MATERIALS AND METHODS 
Tissue specimens and tissue microarray 
For quantitative RT-PCR analysis of PTPRJ mRNA levels, frozen tissue samples of 17 
ccRCCs and matched non-tumorous tissue were used. The pathological parameters of the 
ccRCCs are presented together with the VHL mutations in Table S1 (supplementary data). A 
previously described tissue microarray (TMA) was used [21] to determine PTPRJ mRNA 
expression in ccRCCs, pRCC and normal kidney samples. This study was approved by the 
local commission of ethics (reference number StV. 38-2005). All tissue specimens were 
supplied by the tissue biobank of the University Hospital Zurich. 
 
mRNA quantification  
Quantitative analysis of PTPRJ mRNA expression was performed by qRT-PCR using 17 
ccRCCs with known VHL mutation status. Normal matched tissue was available for each 
tumour and used as control. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and quantified using the Nanodrop spectrometer. Total RNA (0.2 to 1 ȝg) 
was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). The expression of the mRNAs of PTPRJ, HIF-1Į, HIF-
2Į, and GLUT-1 was quantified using the following TaqMan gene expression assays: 
Hs00174561_m1 (PTPRJ), Hs00936376_m1 (HIF-1Į), Hs01026146_m1 (HIF-2Į), and 
Hs00197884_m1 (GLUT-1). The expression assays were designed by Applied Biosystems 
and analysed using the 7900 Fast Real-time PCR System (Applied Biosystems). The data 
were quantified with the comparative Ct method for relative gene expression and normalised 
using PPIA (expression assay Hs99999904_m1) [22].  
 
RNA in situ hybridization (RISH) 
PTPRJ mRNA expression was analysed on a TMA by non-radioactive in situ hybridisation 
adapted from a previously published protocol [23]. Briefly, total mRNA was extracted from 
HeLa cells and the following primers containing the T7 polymerase binding site (5’-
TAATACGACTCACTATAGGGAGAG-3’) were chosen to amplify two parts of the PTPRJ 
mRNA: 5’-GTGAAAGCTCTGGAGCCAAC-3’ and 5’-ACTCCTCATGGCTTCCAATG-3’ 
spanning exons 3-5 and 5’- GAGATCGGCTTAGCATGGAG-3’ and 5’-
TATAAGGTGCCCGGAATCAG-3’ spanning exons 8-9. Digoxigenin (DIG)-labelled 
antisense and sense riboprobes were transcribed in vitro with T7 RNA polymerase in the 
presence of digoxigenin-UTP (Roche Applied Science). For the hybridization procedure 1-2 
µl of DIG-labelled sense and antisense probes (about 100-200 ng) were added to the 
hybridization mix and denatured at 85°C for 5 min. Two ȝm thick TMA sections were 
incubated at 60°C overnight. Detection of probe-target hybrids was performed with 
NBT/BCIP substrate (Roche Applied Science). The intensity of the staining for PTPRJ 
mRNA expression was classified as follows: 0 negative staining, +1 reduced staining, +2 
strong staining. The intensity of staining detected in normal proximal tubules was considered 
as reference for strong staining. 
 
Mutation analysis of PTPRJ and VHL 
For the mutation analysis of PTPRJ genomic DNA was extracted from 32 formalin fixed and 
paraffin embedded ccRCCs which were also on the large TMA. Five normal matched tissues 
were included in the analysis. The mutation analysis of PTPRJ and VHL was performed as 
previously described [16, 24]. Mutations were confirmed with at least one separate PCR and 
sequence analysis. 
 
Cell lines 
The ccRCC cell lines 786-O and RCC4 (transfected with empty vector), 786-O VHL (stably 
expressing pVHL), RCC4 Y98H  and RCC4 Y98N (stably expressing the Type 2A and the 
Type 2B pVHL mutants Y98H and Y98N, respectively) were used in this study. All cell lines 
were grown under conditions recommended by ATCC and authenticated by short tandem 
repeat profiling by Identicell (Department of Molecular Medicine, Aarhus University, 
Hospital Skejby, Aarhus, Denmark). 
 
Western blotting and antibodies 
Total cell lysates were prepared with RIPA buffer (Sigma-Aldrich Corp, Saint Louis, MO, 
USA) supplemented with protease inhibitors (Complete protease inhibitor cocktail, Roche, 
Basel, Switzerland). For cell and tissue fractioning a Nuclear Extraction Kit (Active Motif, 
Carlsbad, CA, USA) and the TissueLyser (Qiagen, Hilden, Germany) were used, respectively. 
Western blot was done as described [6]. Primary antibodies used were anti-pVHL (diluted 
1:500; provided by Wilhelm Krek, ETH Zurich), anti-HIF-1Į (1:1000; Cell Signalling, 
Danvers, MA, USA), anti-HIF-2Į (1:200; NB 100-122, Novus Biologicals, Littleton, CO, 
USA), anti-ȕ-actin (1:1000; Chemicon International, Temecula, CA, USA); anti-PTPRJ (cell 
line extracts) (1:200; H300 sc-22749, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
anti-PTPRJ (cell line and tissue extracts) (1:500; Proteintech, Chicago, IL, USA). Secondary 
antibodies were HRP-conjugated anti-mouse (1:2000; ab672, Abcam) and HRP-conjugated 
anti-rabbit (1:2000; Millipore, Billerica, MA, USA). The protein-antibody complexes were 
detected by using ECL (Amersham, Little Chalfont, Buckinghamshire HP7 7NA United 
Kingdom). Band intensities of PTPRJ and E-Actin from Western blots were measured using 
ImageJ software. 
 
 
Transient transfections 
For RNA interference experiments RCC4, 786-O and HK2 cells were transfected with 5 nM 
siRNA oligonucleotides using HiPerfect transfection reagent (Qiagen). The siRNA sequences 
(Qiagen; Life Technologies, Carlsbad, CA, USA) are listed in Table S2 (supplementary data). 
AllStars Negative controls (Qiagen) was used as negative control.  To study the effects of 
PTPRJ overexpression in RCC4 cells, the pQE-TriSystem-6 vector (Qiagen) containing the 
ORF of the PTPRJ gene (Entrez Gene: 5795, Ensembl: ENSG00000149177, UniProtKB: 
Q12913) was used. The pQE-TriSystem-6 served as control (empty vector). Cells were grown 
for 24 h in a 6-well format and then transiently transfected with the expression vector. Cells 
were harvested after 96 h to evaluate PTPRJ expression levels by qRT-PCR and Western blot. 
 
Luciferase gene reporter assay 
Luciferase gene expression assays were performed as previously described [6]. The 
nucleotides between -2682 and +515 were defined as the putative promoter region of PTPRJ 
(Chr. 11p11.2; 47,971,665:48,222,839, positive strand, NCBI) considering the A(TG) 
translation site as +1 reference. The promoter region was synthesized from GenScript 
(Piscataway, NJ, USA) and cloned into firefly luciferase reporter plasmid pGL4.10 (Promega, 
Madison, WI, USA). pGL4.10P2P vector containing wild type P2P hypoxia response 
elements (HREs) of the human PHD2 promoter were provided by Roland Wenger (University 
of Zurich, Switzerland) and was used as positive control as previously described [6, 25]. 
 
For transcriptional transactivation experiments, 786-O cells were transfected with 
siRNA (HIF-2D #1 or siScr) and grown in a 24-well format. After 48 h the cells were 
transfected with 1 ȝg luciferase reporter plasmid and 200 ng pGL4.74 renilla luciferase 
reporter plasmid (Promega) using FuGene 6 reagent (Roche Molecular Biochemicals). 
Luciferase activity was measured 24 h later after cell lysis using the Dual-Luciferase reporter 
assay system (Promega). Relative luciferase units were determined according to the 
manufacturer’s instructions (Promega) to generate the ratio of the values obtained from siHIF-
2Į and siSc treatments. 
 
MTT proliferation assay 
RCC4 cells were grown in a 6-well format for 24 h and transfected with the expression or 
control vector. MTT proliferation assay (Cell Proliferation Kit I MTT, Roche) was performed 
according to the manufacturer’s protocol. Briefly, transfected cells were plated in a 96-well 
plate. After the incubation period, 10 ȝl of the MTT labelling reagent (final concentration 0.5 
mg/ml) was added to each well and cells were incubated for 4 h. Subsequently, 100 ȝl of the 
solubilisation solution was added to the wells and cells were incubated overnight at 37°C. The 
solubilized formazan product was quantified using an ELISA reader (Tecan, Infinite f200) at 
wavelength 570 nm. The analysis of cell proliferation was performed after 96 h, 120 h, 144 h 
and 168 h.  
 
Statistical analysis 
Analysis between groups was done with 2-way ANOVA and post-hoc Bonferroni multiple 
comparison (GraphPad Prism 5). Contingency table analysis and Pearson’s Chi-squared tests 
were calculated using SPSS 17.0 statistical software package. Survival curves were estimated 
with the Kaplan–Meier method and the log rank test. P values < 0.05 were considered 
statistically significant.  
 RESULTS 
Direct correlation of PTPRJ and pVHL expression in RCC cell lines 
Previous mass spectrometry experiments performed with pVHL-deficient and pVHL-re-
expressing RCC cell lines identified PTPRJ positively linked to pVHL expression [8]. To 
confirm that PTPRJ is influenced by the VHL/HIF axis we used the pVHL-deficient renal 
cancer cell lines 786-O and RCC4 and their corresponding stable pVHL transfectants. 
Compared to the correspondent pVHL-negative cell lines both PTPRJ mRNA (Fig. 1A) and 
protein levels (Fig. 1B and 1C) were increased in the presence of pVHL. 
 
PTPRJ mRNA expression is decreased in ccRCC tissue 
To quantitatively evaluate PTPRJ mRNA expression in human RCC samples we performed 
qRT-PCR with 17 ccRCCs and normal matched tissues. PTPRJ expression was reduced in 15 
of 17 ccRCCs (88 %) (Fig. 1D) when compared to normal renal tissues. A strong PTPRJ 
expression was seen in one VHL wild type tumour and in one ccRCC with a missense 
mutation that causes an amino acid exchange at codon 88 (Fig. 1D, Table S1). Western blot 
analysis with three matched normal/tumour pairs demonstrated a direct correlation between 
mRNA and protein expression of PTPRJ (Fig. 1E).  
 
As commercially available PTPRJ antibodies were not specific in formalin fixed and 
paraffin embedded tissues, the expression of PTPRJ was analysed by RNA in situ 
hybridization (RISH). The specificity of DIG-labelled RNA probes for PTPRJ was confirmed 
by Northern Blot analysis using total RNA from HeLa cells (positive control). The antisense 
probes bound a 7.8 kb band corresponding to the PTPRJ transcript (data not shown). 
  
PTPRJ RISH analysis on a TMA showed strong positivity in the proximal tubular 
cells of all analysed normal kidney tissue samples (Fig. 2), whereas in 198 of 232 (85 %) 
analysable ccRCCs, but in only 5 of 41 (12 %) of pRCCs PTPRJ expression was reduced (p < 
0.001). ccRCC patients with no or low PTPRJ mRNA expression showed a worse prognosis 
than those with a normal expression status (p=0.05) (Fig. 3). No associations were seen 
between PTPRJ expression and tumour stage and grade. The highly significant difference 
between the survival curves of patients with organ-confined and locally advanced tumours 
confirmed the validity of the clinical data (Fig S2). 
 
Mutation analysis of PTPRJ in ccRCC 
Twenty-two PTPRJ negative and 10 weakly expressing ccRCC samples included in 
the TMA were selected for mutation analysis of exons 5, 6, 7 and 13 of PTPRJ. So far, all 
cancer-related amino-acid substitutions were identified in these four exons which code the 
extracellular portion responsible for interactions with ligands or other proteins [16]. Five 
normal matched tissues were also included in this analysis. We found two conservative 
(E206E and T233T) and three non-conservative (Q276P, R326Q and E872D) polymorphisms 
which were previously reported (UniprotKB/Swiss-Prot, Q12913 (PTPRJ_HUMAN)). There 
were no mutations affecting the reading frame of PTPRJ. 
 
PTPRJ expression is HIF-2Į-dependent  
To determine the influence of the pVHL-HIF axis on PTPRJ expression we used 
different pVHL expressing and non-expressing RCC cell lines. In RCC4 cells expressing the 
pVHL mutant Y98N, which fail to degrade HIF-Į [26], PTPRJ mRNA expression was 
comparable to pVHL-deficient RCC4. In contrast, RCC4 cells expressing the pVHL mutant 
Y98H, which has only a slight defect in ubiquitination of HIF-Į [26], the PTPRJ mRNA level 
was increased and similar to the RCC4 VHL cell line (Fig. 4A). An opposite effect was 
observed with GLUT1 mRNA whose expression increased in the presence of HIF-Į (Fig. 4B).   
 
 Next, we silenced HIF-1Į and HIF-2Į by siRNA in the pVHL-deficient RCC4 cell 
line to determine whether the two HIF-Į isoforms were able to down-regulate PTPRJ mRNA 
expression. Efficient knock down of HIF-1Į and HIF-2Į was confirmed by qRT-PCR and 
Western blot analysis (Fig. 4C-G). In RCC4, silencing of HIF-1Į had positive effects on 
PTPRJ mRNA expression after 48 h (Fig. 5A). In contrast, silencing of HIF-2Į produced an 
increase of PTPRJ mRNA expression already after 24 h and reached a 2-fold up-regulation 
after 48 h (Fig. 5B). We also silenced HIF-2Į by siRNA in the pVHL and HIF-1Į-null 786-
O cell line. After 48 h we obtained an increase of PTPRJ mRNA expression which was 
comparable to that observed in 786-O VHL (Fig. 5D). Efficient knock down of HIF-2Į was 
confirmed by analysing the level of GLUT-1 mRNA (Fig. 5F). Western blot analysis 
confirmed a strong increase of PTPRJ protein expression in both HIF-2Į silenced ccRCC cell 
lines (Fig. 5C and E). Similar results were obtained with two additional HIF-2D siRNAs 
excluding possible off target effects (Fig. S1 A-C). 
 
HIF response elements in the promoter region influence PTPRJ expression 
The putative promoter region of PTPRJ contains five HREs and three reverse HREs (Table 
S3, Fig. 6A). To study the influence of the HREs on PTPRJ expression a luciferase reporter 
plasmid pGL4.10 construct containing 3.2kb of the PTPRJ promoter was generated (Fig. 6A). 
By silencing HIF-2D in 786-O cells (Fig. 6B) the reporter activity of the vector increased 
significantly compared to those of the empty plasmid and the P2P promoter construct (Fig. 
6C). These results show that HIF-2D negatively regulates PTPRJ via the identified putative 
HREs in its promoter region. 
 
PTPRJ regulates cell proliferation 
RCC4 cells transfected with Qiagen expression vector pQE-TriSystem 6 containing the 
PTPRJ gene showed increased mRNA and protein expression of PTPRJ (Fig. 6D and 6E).  
RCC4 cells transfected with the PTPRJ vector showed a significant reduced proliferation rate 
compared to the control group (Fig. 6F).  
We also silenced PTPRJ by siRNA in wild type pVHL expressing HK2 to see if 
PTPRJ down regulation leads to increased cell proliferation in the presence of pVHL. 
Reduced expression negatively influenced cell proliferation after 72 h (Fig. S3A-B) and 
suggests that loss of PTPRJ is biologically relevant to promote growth of ccRCC, 
independently from the pVHL expression status.  
 
 
DISCUSSION 
We have demonstrated that decreased PTPRJ expression is characteristic for the vast majority 
of ccRCC. In vitro experiments showed that higher PTPRJ mRNA and protein expression 
levels are closely linked to the presence of functional pVHL. Down-regulation of PTPRJ is 
mainly dependent on HIF-2Į stabilisation following pVHL loss.   
 
Our TMA analysis showed no or low PTPRJ mRNA expression in 85 % of ccRCCs, 
whereas in most of the pRCCs PTPRJ mRNA levels were comparable to those in normal 
tissues. The fact that VHL is mutationally affected in about 70-80 % of ccRCCs [1, 27, 28], 
suggests a close relationship between PTPRJ mRNA expression and pVHL functional 
integrity. This is supported by the observation that PTPRJ expression was normal in almost 
90 % of the analysed pRCC in which VHL is hardly mutated [29]. This result confirms our 
recent proteomics finding of a relationship between PTPRJ expression and pVHL in human 
tissue [8]. In our test set of 17 ccRCC reduced PTPRJ mRNA expression was also seen in two 
of four tumours with wild type VHL. Other mechanisms of VHL inactivation, such as tumour 
hypoxia or hypermethylation of the VHL promoter, which occurs in about half of VHL wild 
type ccRCC [1, 28, 30], may explain this observation. 
 
Here, we identified PTPRJ as potential target of HIF-2Į. HIF-1Į and HIF-2Į share 
high similarity in their DNA binding and dimerization domains, but they differ in their 
transactivation domains [31]. As a consequence, there are common gene targets, but also 
genes that are preferentially regulated by one of the two isoforms. HIF-1Į seems to 
preferentially drive the transcription of genes encoding glycolytic enzymes and pro-apoptotic 
factors, such as BCL2/adenovirus E1B–interacting protein 1, NIP3 (BNIP3). In contrast, HIF-
2Į induces the expression of pro-survival factors such as VEGF, TGF-Į, and CCND1 [32]. 
Studies demonstrated that HIF-Į can also down-regulate genes either by inducing repressors 
of transcription and by directly binding to hypoxia response elements (HREs) or to reverse 
HREs. The latter are present in the antisense strand of the promoter of HIF target genes. 
Examples of genes directly down-regulated by HIF-1Į are Į-fetoprotein [33], PPAR-Į [34] 
and RECK [35], whereas genes directly or indirectly down-regulated by HIF-2Į have not 
been described to date. 
 
The analysis of the putative PTPRJ promoter showed the presence of five putative 
HREs and three putative reverse HREs. Since we observed PTPRJ down-regulation in the 
presence of HIF-2Į, we asked whether HIF could directly act as suppressor of PTPRJ 
transcription. Using 786-O cells, significant effects were seen with our luciferase gene 
reporter assays suggesting that the HREs and reverse HREs identified in the putative PTPRJ 
promoter region are important for suppressing PTPRJ expression by HIF-2Į. It is of note that 
only a two-fold overexpression of PTPRJ in RCC4 cells was sufficient to produce a 
significant inhibitory effect on cell proliferation. Our result expands the findings of previous 
studies that describe anti-proliferative properties of PTPRJ in non-RCC tumour cell lines [10, 
12, 14]. 
 
To evaluate the presence of mutations of the PTPRJ gene, we performed a sequence 
analysis of the exons 5, 6, 7 and 13 of PTPRJ in 32 ccRCCs. We found two conservative and 
three non-conservative polymorphisms, but no mutation predicting severe consequences on 
PTPRJ function. Similar frequencies of these polymorphisms were found in studies which 
analysed the PTPRJ genotype in other tumour types and in other populations [36-38]. The real 
influence of these polymorphisms on PTPRJ expression and function is still not fully 
understood. Our results suggest that in ccRCC the down-regulation of PTPRJ expression is 
obviously not caused by mutations but mainly due to the deregulation of the pVHL/HIF 
pathway (Fig. 7). 
 
PTPRJ’s inhibitory effect on cell proliferation in ccRCC, as shown by us, and in other 
tumour types [14, 39 , 40 ] as well as its ability to regulate EGFR phosphorylation [17] 
suggest its important influence on the activity of EGFR. Although EGFR over-expression 
occurs in the majority of ccRCC and is correlated with rapid tumour cell proliferation and 
worse patient outcome [41, 42], anti-EGFR targeted therapies have shown only low response 
rates [43, 44]. As demonstrated in non-small cell lung cancer, the success of such therapies is 
obviously dependent on EGFR activating mutations [45] which have not been found in 
ccRCC [41]. Antibodies against phosphorylated and activated EGFR are available but their 
use for reliably determining its tyrosine kinase activity status on formalin fixed, paraffin 
embedded tissue in routine diagnostics is challenging [46]. Despite the low number of tumors 
analysed, our Western blot data indicate reduced PTPRJ expression also at the protein level in 
a subset of ccRCC. It is conceivable that EGFR positive tumours with strongly reduced 
PTPRJ may better respond to inhibitors against EGFR and its downstream targets, such as 
PI3K, AKT and mTOR, than those showing normal PTPRJ expression. However, additional 
experiments using optimized antibodies as well as appropriate mouse models are needed to 
characterize the biological relevance of PTPRJ down regulation by the pVHL/HIF axis and its 
clinical applicability for this tumour subtype. 
 
In summary, we show that down-regulation of PTPRJ is a characteristic feature in 
ccRCC that is closely linked to the loss of pVHL function and the activation of HIF. 
Molecular studies of low abundant genes, such as PTPRJ, are a big challenge in cancer 
research as they are more sophisticated compared to investigations of those genes that become 
clearly up or down-regulated in tumours. They are nevertheless necessary to better understand 
the complex genetic network of cancer. 
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FIGURE LEGENDS 
 
Figure 1. Positive correlation between PTPRJ and pVHL expression. A) PTPRJ mRNA 
levels measured by qRT-PCR (3 replicas ± SD) in pVHL-negative RCC cell lines and their 
stable VHL transfectants (increase 1.5 to 1.9-fold). B) Western blot showing PTPRJ protein 
expression in VHL-negative ccRCC cells and their stable VHL transfectants (loading control: 
ȕ-Actin). C) Elevated PTPRJ expression in pVHL expressing 786-O (normalized mean 1.73 + 
0.42 SD, n = 5, p = 0.026) and RCC4 cells (1.51 + 0.64, n = 4, p = ns.). D) Normalized 
PTPRJ mRNA levels measured by qRT-PCR in 17 ccRCCs and their normal matched tissues 
(3 replicas ± SD). The VHL mutation status in the tumours is indicated (wt = wild type, ms = 
missense, del fs = deletion leading to frameshift, del ins = deletion and insertion, delX = 
deletion leading to a stop codon). E) Western blot showing PTPRJ protein expression in three 
ccRCC tissues and matched normal tissues (loading control: ȕ-actin). Significant differences 
(p < 0.05) are indicated by asterisks. 
 
Figure 2. PTPRJ RISH on a TMA with examples for negative, reduced and strong PTPRJ 
mRNA expression in ccRCC and normal kidney. 
 
Figure 3. Kaplan-Meier plot of overall survival of ccRCC patients defined by PTPRJ mRNA 
expression. Survival data were not available from 18 patients. PTPRJ expression was defined 
reduced if the mRNA staining in a tumor was unequivocally weaker compared to that seen in 
normal kidney.   
 
Figure 4. A) PTPRJ mRNA transcription in RCC4 VHL, RCC4 Y98H (HIF-D destabilising 
VHL mutation) and RCC4 Y98N (HIF-D non-destabilising VHL mutation) cells. B) GLUT-1 
mRNA expression in the same RCC4 cells. C and D) Knock down efficiency of siHIF-1Į and 
siHIF-2Į on HIF-1Į (C) and HIF-2Į (D) mRNA expression after 24 h and 48 h in RCC4 
cells. E) Western blot showing down-regulated HIF-1Į and HIF-2Į protein expression in 
RCC4 cells. F) HIF-2Į mRNA expression in siHIF-2D transfected 786-O cells after 24 h and 
48 h. G) Western blot showing down-regulated HIF-2Į protein expression  (loading control: 
ȕ-actin). Significant differences (p < 0.05) of PTPRJ, GLUT-1, HIF-1D and HIF-2D 
expression compared to wild type cell lines are indicated by asterisks. 
 
 Figure 5. PTPRJ expression depends mainly on HIF-2D. A) Increase of PTPRJ mRNA 
expression in RCC4 cells after silencing of HIF-1Į and B) after silencing of HIF-2Į. C) 
Western blot showing PTPRJ protein expression in RCC4 cells after silencing of HIF-1Į and 
HIF-2Į. D) Increase of PTPRJ mRNA levels in 786-O cells after silencing of HIF-2Į. E) 
PTPRJ protein expression after silencing of HIF-2Į. F) GLUT-1 mRNA expression in HIF-2Į 
silenced 786-O cells. Data represent mean of two experiments done in triplicate ± SD. 
Significant differences (p < 0.05) of PTPRJ and GLUT-1 expression compared to wild type 
cell lines are indicated by asterisks. 
 Figure 6. PTPRJ promoter activity is HIF-2Į dependent. A) Schematic representation of the 
3.2 kb PTPRJ promoter with the location of the five HREs and three reverse HREs. B) 
Western blot showing efficient knock down of HIF-2Į in 786-O cells after 72 h (loading 
control: ȕ-actin). C) Luciferase reporter gene assay with P2P (HIF target) and PTPRJ vector 
constructs after transient transfection of siScrambled and siHIF-2Į using 786-O cells. 
Decrease of P2P and increase of PTPRJ promoter activity after HIF-2Į silencing. D) PTPRJ 
mRNA levels measured by qRT-PCR in RCC4 cells untreated, transfected with scrambled 
control and with PTPRJ expression vector 96 h after transfection. Data represent mean of 3 
replicas ± SD. E) Immunoblot of PTPRJ expression in RCC4 cells untreated, transfected with 
scrambled control and with PTPRJ expression vector 96 h after transfection. RQ = relative 
quantification. F) Proliferation of RCC4 cells 96 h, 120 h, 144 h and 168 h after transfection 
with empty vector (control) or PTPRJ expression vector (PTPRJ). 
 
Figure 7. Schematic representation of the HIF-Į dependent regulation of PTPRJ expression 
in normal kidney and ccRCC. 
 
 
 
 
 
 
 
 
SUPPLEMENTARY DATA 
 
Figure S1. A) Western blot showing HIF-2Į down regulation in 786-O cells with three 
different siHIF-2D (siHIF-2Į #1, siHIF-2Į #2, siHIF-2Į #3) to exclude off target effects for 
changed PTPRJ expression. B) Increased PTPRJ mRNA levels in 786-O cells and C) in 
RCC4 cells after silencing of HIF-2Į with siHIF-2Į #2. 
 
Figure S2. Kaplan-Meier plot of overall survival of ccRCC patients with organ-confined 
(stage pT1/pT2) and locally advanced tumors (pT3/pT4). 
 
Figure S3. A) Western blot showing PTPRJ down regulation in HK2 cells 72 h after 
transfection. B) Proliferation of HK2 cells 24 h, 48 h, 72 h and 96 h after transfection of 
siPTPRJ and siScramled (control). 
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